𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Obsessive–compulsive disorder: treatment and treatment resistance

✍ Scribed by Philip Cohen


Publisher
Informa plc
Year
2001
Tongue
English
Weight
78 KB
Volume
9
Category
Article
ISSN
1039-8562

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Obsessive–compulsive disorder: treatment
✍ Sean Hood; Deirdre Alderton; David Castle 📂 Article 📅 2001 🏛 Informa plc 🌐 English ⚖ 147 KB

Objective: To review the treatment options for obsessive–compulsive disorder (OCD), with particular reference to treatment resistance, and provide a guideline for clinicians managing these patients, drawing upon evidence from clinical trials and expert consensus. Conclusions: The behavioural techni

Current treatment approaches to obsessiv
✍ Beth K. Boyarsky; Lynn A. Perone; Nicole C. Lee; Wayne K. Goodman 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 859 KB

The two most useful treatments in obsessive-compulsive disorder are pharmacotherapy with potent serotonin reuptake-blocking agents and behavioral techniques, such as exposure and response prevention. Based on the authors' cumulative clinical experience, it is suggested that patient education, cognit

SSRIs in the Treatment of obsessive-comp
✍ Charles Cartwright; Eric Hollander 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 2 views

The introduction of the SSRIs (selective serotonin reuptake inhibitors) over the past decade has provided exciting new opportunities for the treatment of obsessive-compulsive disorder (OCD). The serotonin hypothesis, based on the preferential response of OCD to the serotonin reuptake inhibitor, clom

Amisulpiride augmentation in treatment r
✍ Özmen Metin; Kemal Yazici; Senel Tot; Aylin Ertekin Yazici 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsyc